Ongoing Investigation of RLY-4008 Highlights Evolving Treatment Options for FGFR2+ Cholangiocarcinoma

R. Kate Kelley, MD, details the ongoing investigation of RLY-4008 for patients with advanced cholangiocarcinoma harboring FGFR2 fusions or rearrangements, other ongoing investigations in cholangiocarcinoma, and the importance of molecular testing to drive treatment decisions in this population.

Related Keywords

California ,United States ,San Francisco ,Antoine Hollebecque ,Lipika Goyal ,R Kate Katie Kelley ,Department Of Medicine Hematology Oncology ,Virtual International Conference On Molecular ,Cancer Immunotherapy Program ,University Of California ,International Conference ,Molecular Targets ,Cancer Therapeutics ,